Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease

Journal of the American College of Cardiology

Volumn 64, Issue 23, 2014, Pages 2525-2540

  Rosenson, Robert S ^a   Davidson, Michael H ^b   Hirsh, Benjamin J ^c   Kathiresan, Sekar ^d   Gaudet, Daniel ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Atherosclerosis; Cardiovascular disease; Genetics; Triglyceride; Triglyceride rich lipoproteins

Indexed keywords

ACYLTRANSFERASE INHIBITOR; ALIPOGENE TIPARVOVEC; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CHYLOMICRON; DIACYLGLYCEROL ACYLTRANSFERASE 1; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; LIPOPROTEIN; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; MEDIUM CHAIN TRIACYLGLYCEROL; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRIGLYCERIDE RICH LIPOPROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CONCENTRATION (PARAMETERS); DIET RESTRICTION; DNA POLYMORPHISM; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; FAT TOLERANCE TEST; FATTY ACID BLOOD LEVEL; GENE REPLACEMENT THERAPY; GENE SEQUENCE; GENE STRUCTURE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; BLOOD; CARDIOVASCULAR DISEASES; DNA SEQUENCE; GENETIC VARIABILITY; GENETICS; INTESTINE; LIVER; METABOLISM;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; FASTING; FATTY ACIDS, OMEGA-3; GENETIC VARIATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INTESTINES; LIPOPROTEINS; LIVER; POSTPRANDIAL PERIOD; SEQUENCE ANALYSIS, DNA; TRIGLYCERIDES;

EID: 84925469494     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.09.042     Document Type: Review

References (155)

1. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-8.
2. Tirosh A, Rudich A, Shochat T, et al. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 2007;147: 377-85.
3. Sarwar N, Sandhu MS, Ricketts SL, et al., for the Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-9.
4. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333.
5. Hegele RA, Ginsberg HN, Chapman MJ, et al., on behalf of the European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014;2:655-66.
6. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selectedaffinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994;14:1767-74.
7. Tomkin GH, Ownes D. Abnormalities in apoBcontaining lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev 2001;17:27-43.
8. Vine DF, Glimm DR, Proctor SD. Intestinal lipid transport and chylomicron production: possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome. Atheroscler Suppl 2008;9:69-76.
9. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, Apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000;102: 1886-92.
10. Zheng C, Khoo C, Furtado J, et al. Apolipoprotein C-II and the metabolic bases for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 2010;121:1722-34.
11. Mendivil CO, Rimm EB, Furtado J, et al. Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease. J Am Heart Assoc 2013; 2:e000130.
12. Dashty M, Motazacker MM, Levels J, et al. Proteome of human plasma very low-density lipoprotein and low-density lipoprotein exhibits a link with coagulation and lipid metabolism. Thromb Haemost 2014;111:518-30.
13. Demignot S, Deilstein F, Morel E. Triglyceriderich lipoproteins and cytosolic lipid droplets in enterocytes: key players in intestinal physiology and metabolic disorders. Biochimie 2014;96:48-55.
14. Cases S, Stone SJ, Zhou P, et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 2001;276:38870-6.
15. Rashid S, Tavori H, Brown PE, et al. Preprotein convertase cubtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein-B lipoproteins through both LDLreceptor dependent and independent mechanisms. Circulation 2014;130:431-41.
16. Siddiqi SA, Mansbach CM 2nd PKCzmediated phosphorylation controls budding of the pre-chylomicron transport vesicle. J Cell Sci 2008; 121:2327-38.
17. Zhu J, Lee B, Buhman KK, et al. A dynamic, cytoplasmic triacylglycerol pool in enterocytes revealed by ex vivo and in vivo coherent anti- Stokes Raman scattering imaging. J Lipid Res 2009;50:1080-9.
18. Bouchoux J, Beilstein F, Pauquai T, et al. The proteome of cytosolic lipid droplets isolated from differentiated Caco-2/TC7 enterocytes reveals cell-specific characteristics. Biol Cell 2011;103: 499-517.
19. Adiels M, Matikainen N, Westerbacka J, et al. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis 2012;222: 222-8.
20. Haidari M, Leung N, Mahbub F, et al. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem 2002;277:31646-55.
21. Sundaram M, Zhong S, Bou Khalil M, et al. Expression of apolipoprotein C-II in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res 2010;51: 150-61.
22. Gusarova V, Brodsky JL, Fisher EA. Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER. J Biol Chem 2003;278:48051-8.
23. Ye J, Li JZ, Liu Y, et al. Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B. Cell Metab 2009;9:177-90.
24. Wong H, Schotz MC. The lipase gene family. J Lipid Res 2002;43:993-9.
25. Berbée JF, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PC. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res 2005;46:297-306.
26. Larsson M, Vorrsjö E, Talmud P, et al. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem 2013;288: 33997-4008.
27. Kinnunen PK, Jackson RL, Smith LC, et al. Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II. Proc Natl Acad Sci U S A 1977;74: 4848-51.
28. Ginsberg HN, Le NA, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apo-lipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986;78:1287-95.
29. Grosskopf I, Baroukh N, Lee SJ, et al. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol 2005;25:2573-9.
30. Shimizugawa T, Ono M, Shimamura M, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem 2002;277:33742-8.
31. Koster A, Chao YB, Mosior M, et al. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 2005;146:4943-50.
32. Sukonina V, Lookene A, Olivecrona T, et al. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci U S A 2006;103:17450-5.
33. Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A 2012;109: 19751-6.
34. Kersten S, Mandard S, Tan NS, et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 2000;275: 28488-93.
35. Liu J, Afroza H, Rader DJ, et al. Angiopoietinlike protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases. J Biol Chem 2010;285:27561-70.
36. Zheng C, Murdoch SJ, Brunzell JD, et al. Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans. Arterioscler Thromb Vasc Biol 2006;26:891-6.
37. Oka K, Ishimura-Oka K, Chu MJ, et al. Mouse very-low density-lipoprotein receptor (VLDLR) cDNA cloning, tissue-specific expression and evolutionary relationship with the low-density lipoprotein receptor. Eur J Biochem 1994;224: 975-82.
38. Webb JC, Patel DD, Jones MD, et al. Characterization and tissue-specific expression of the human "very low density lipoprotein (VLDL) receptor" mRNA. Hum Mol Genet 1994;3:531-7.
39. Multhaupt HA, Gafvels ME, Kariko K, et al. Expression of very low density lipoprotein receptor in the vascular wall. Analysis of human tissues by in situ hybridization and immunohistochemistry. Am J Pathol 1996;148:1985-97.
40. Gao Y, Shen W, Zhang Q, et al. Upregulation of hepatic VLDLR via PPARa is required for the triglyceride-lowering effect of fenofibrate. J Lipid Res 2014;55:1622-33.
41. Curtiss LK. ApoE in atherosclerosis: a protein with multiple hats. Arterioscler Thromb Vasc Biol 2000;20:1852-3.
42. Wang YI, Schultze J, Raymond N, et al. Endothelial inflammation correlates with subject triglycerides and waist size after a high-fat meal. AJP Heart Circ Physiol 2011;300:H784-91.
43. Sun C, Alkhoury K, Wang YI, et al. IRF-1 and miRNA126 modulate VCAM-1 expression in response to a high fat meal. Circ Res 2012;111: 1054-64.
44. Gower RM, Wu H, Foster GA, et al. CD11c/ CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2011;31:160-6.
45. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-61.
46. Civelek M, Manduchi E, Riley RJ, et al. Chronic endoplasmic reticulum stress activates unfolded protein response in arterial endothelium in regions of susceptibility to atherosclerosis. Circ Res 2009; 105:453-61.
47. Wang YI, Bettaieb A, Sun C, et al. Triglyceriderich lipoprotein modulates endothelial vascular cell adhesion molecule (VCAM)-1 expression via differential regulation of endoplasmic reticulum stress. PLoS One 2013;8:e78322.
48. Wang L, Gill R, Pedersen TL, et al. Triglyceride- rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 2009;50:204-13.
49. Wang L, Sapuri-Butti AR, Aung HH, et al. Triglyceride-rich lipoprotein lipolysis increases aggregation of endothelial cell membrane microdomains and produces reactive oxygen species. Am J Physiol Heart Circ Physiol 2008;295: H237-44.
50. Aung HH, Lane MW, Gohil K, et al. Induction of ATF3 gene network by triglyceride-rich lipoprotein lipolysis products increases vascular apoptosis and inflammation. Arterioscler Thromb Vasc Biol 2013; 33:2088-96.
51. Rutledge JC, Mullick AE, Gardner G, et al. Direct visualization of lipid deposition and reverse lipid transport in a perfused artery: roles of VLDL and HDL. Circ Res 2000;86:768-73.
52. Laugerette F, Vors C, Peretti N, et al. Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation. Biochimie 2011;93:39-45.
53. Berglund L, Brunzell JD, Goldberg AC, et al., for the Endocrine Society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2969-89.
54. Chapman MJ, Ginsberg HN, Amarenco P, et al., for the European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32: 1345-61.
55. Guerin M, Egger P, Soudant C, et al. Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J Lipid Res 2002;43:1652-60.
56. Rosenson RS, Helenowski IB, Tangney CC. Heterogenous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy. Cardiovasc Drugs Ther 2010; 24:439-47.
57. Grundy SM, Mok HY. Chylomicron clearance in normal and hyperlipidemic man. Metabolism 1976; 25:1225-39.
58. Lassel TS, Guerin M, Auboiron S, et al. Preferential cholesteryl ester acceptors among triglyceride-rich lipoproteins during alimentary lipemia in normolipidemic subjects. Arterioscler Thromb Vasc Biol 1998;18:65-74.
59. Cohn JS, McNamara Jr., Cohn SD, et al. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988;29: 469-79.
60. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008;118:2047-56.
61. Lee SH, Lee BW, Won HK, et al. Postprandial triglyceride is associated with fasting triglyceride and HOMA-IR in Korean subjects with type 2 diabetes. Diabetes Metab J 2011;35:404-10.
62. Ridker PM. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin Chem 2008;54:11-3.
63. Rosenson RS, Wolff DA, Huskin AL, et al. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response among hypertriglyceridemia subjects with the metabolic syndrome. Diabetes Care 2007;30:1945-51.
64. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298: 309-16.
65. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308.
66. Karpe F, Hamsten A. Postprandial lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 1995;6:123-9.
67. Perez-Martinez P, Delgado-Lista J, Perez- Jimenez F, et al. Update on genetics of postprandial lipemia. Atheroscler Suppl 2010;11: 39-43.
68. Jackson KG, Clarke DT, Murray P, et al. Introduction to the DISRUPT postprandial database: subjects, studies and methodologies. Genes Nutr 2009;5:39-48.
69. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85.
70. Di Angelantoni E, Sarwar N, Perry P, et al., for the Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
71. Mamo JC, Proctor SD, Smith D. Retention of chylomicron remnants by arterial tissue: importance of an efficient clearance mechanism from plasma. Atherosclerosis 1998;141 Suppl 1:S63-9.
72. Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013;61: 427-36.
73. Jørgensen AB, Frikke-Schmidt R, West AS, et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013;34:1826-33.
74. Jackson KG, Poppitt SD, Minihane AM, et al. Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants. Atherosclerosis 2012;220:22-33.
75. Pennachio LA, Olivier M, Hubacek JA, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001;294:169-73.
76. Lai CQ, Demissie S, Cupples LA, et al. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J Lipid Res 2004;45: 2096-105.
77. Elosua R, Ordovas JM, Cupples LA, et al. Variants at the ApoA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study. J Lipid Res 2006;47:990-6.
78. Lai CQ, Arnett DK, Corella D, et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol 2007;27:1417-25.
79. McPherson R. Remnant cholesterol: "Non- (HDL-C + LDL-C)" as a coronary artery disease risk factor. J Am Coll Cardiol 2013;61:437-9.
80. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012;307:1302-9.
81. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
82. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-934.
83. Robinson JG, Wang S, Smith BJ, et al. Metaanalysis of the relationship between non-highdensity lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009;53:316-22.
84. Rosenson RS. Management of non-highdensity lipoprotein abnormalities. Atherosclerosis 2009;207:328-35.
85. Hoogeveen RC, Gaubatz JW, Sun W, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol 2014; 34:1069-77.
86. Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipid and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009;119:931-9.
87. Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 2010;213:1-7.
88. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008;51:1512-24.
89. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009;55:407-19.
90. DavidsonMH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatorymarkers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol 2011;5:338-67.
91. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement-executive summary. Endocr Pract 2013;19:536-57.
92. Catapano AL, Reiner Z, De Backer G, et al. ESC/ EAS guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217:3-46.
93. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel Members. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia- full report. J Clin Lipidol 2014;8:29-60.
94. Expert Panel on Dyslipidemia. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia: executive summary. Atherosclerosis 2014;232:410-3.
95. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006;259:247-58.
96. Folsom AR, Peacock JM, Demerath E, Boerwinkle E. Variation in ANGPTL4 and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Metabolism 2008;57:1591-6.
97. Romeo S, Yin W, Kozlitina J, et al. Rare lossof- function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest 2009;119:70-9.
98. Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010;363: 2220-7.
99. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008;322:1702-5.
100. Saxena R, Voight BF, Lyssenko V, et al., for the Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316: 1331-6.
101. Peloso GM, Auer PL, Bis JC, et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet 2014;94:223-32.
102. Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008;40:161-9.
103. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008;40:189-97.
104. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009;41:56-65.
105. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-13.
106. Willer CJ, Schmidt EM, Sengupta S, et al., for the Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013;45:1274-83.
107. Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res 2011;52:189-206.
108. Johansen CT, Wang J, Lanktree MB, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010;42:684-7.
109. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013; 45:1345-52.
110. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014;371:22-3.
111. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014;371:32-41.
112. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81:66B-9B.
113. Tremblay K, Méthot J, Brisson D, et al. Etiology and risk of lactescent plasma and severe hypertriglyceridemia. J Clin Lipidol 2011;5:37-44.
114. Marx N, Duez H, Fruchart JC, et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004;94:1168-78.
115. Mansouri RM, Baugé E, Gervois P, et al. Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia. Circ Res 2008;103:450-3.
116. Yan F, Wang Q, Xu C, et al. Peroxisome proliferator-activated receptor a activation induces hepatic steatosis, suggesting an adverse effect. PLoS One 2014;9:e99245.
117. Rogue A, Anthérieu S, Vluggens A, et al. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. Toxicol Appl Pharmacol 2014;276: 73-81.
118. Ganji SH, Kukes GD, Lambrecht N, et al. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2014;306:G320-7.
119. HPS 2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12.
120. Anderson TJ, Boden WE, Desvigne-Nickens P, et al., for the AIM-HIGH Investigators. Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med 2014;371:288-90.
121. Bang HO, Dyerberg J, Nielsen A. Plasma lipid and lipoprotein pattern in in Greenlandic Westcoast Eskimos. Lancet 1971;297:1143-5.
122. Davidson MH. Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol 2013;24: 467-74.
123. Couturier A, Keller J, Most E, et al. Niacin in pharmacological doses alters microRNA expression in skeletal muscle of obese Zucker rats. PLoS One 2014;9:e98313.
124. Chai JT, Digby JE, Ruparelia N, et al. Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells. PLoS One 2013;8:e62934.
125. Kamanna VS, Ganji SH, Kashyap ML. Recent advances in niacin and lipid metabolism. Curr Opin Lipidol 2013;24:239-45.
126. Ouellette C, Cormier H, Rudkowska I, et al. Polymorphisms in genes involved in the triglyceride synthesis pathway and marine omega-3 polyunsaturated fatty acid supplementation modulate plasma triglyceride levels. J Nutrigenet Nutrigenomics 2013;6:268-80.
127. Kastelein JJ, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol 2014;8:94-106.
128. Gil-Zamorano J, Martin R, Daimiel L, et al. Docosahexaenoic acid modulates the enterocyte Caco-2 cell expression of microRNAs involved in lipid metabolism. J Nutr 2014;144:575-85.
129. Schaeffer L, Gohlke H, Muller M, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 2006;15:1745-56.
130. Deo RC, Reich D, Tandon A, et al. Genetic differences between the determinants of lipid profile phenotypes in African and European Americans: the Jackson Heart Study. PLoS Genet 2009;5:e1000342.
131. Martinelli N, Girelli D, Malerba G, et al. FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. Am J Clin Nutr 2008;88:941-9.
132. Lemaitre RN, Tanaka T, Tang W, et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet 2011;7:e1002193.
133. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 2006;98:27i-33i.
134. Kawakami A, Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb 2009;16:6-11.
135. Jump DB, Botolin D, Wang Y, et al. Fatty acid regulation of hepatic gene transcription. J Nutr 2005;135:2503-6.
136. Iizuka K, Horikawa Y. ChREBP: a glucoseactivated transcription factor involved in the development of metabolic syndrome. Endocr J 2008;55:617-24.
137. Chen YJ, Chen CC, Li TK, et al. Docosahexaenoic acid suppresses the expression of FoxO and its target genes. J Nutr Biochem 2012;23:1609-16.
138. Davidson MH, Maki KC, Bays H, et al. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoproteinassociated phospholipase A2 mass in statintreated subjects with hypertriglyceridemia. J Clin Lipidol 2009;3:332-40.
139. Pilot study to assess CAT-2003 in patients with severe hypertriglyceridemia. Updated March 7, 2014. Available at: http://clinicaltlableatrials.gov/ct2/show/NCT01968720. Accessed September 22, 2014.
140. Catabasis Pharmaceuticals, Inc. Catabasis describes modulation of SREBP as mechanism for CAT-2003. May 1, 2014. Available at: http://www. catabasis.com/pdfs/CatabasisATVB2014DataFINAL050114.pdf. Accessed September 22, 2014.
141. Gaudet D, Alexander VJ, Brisson D, et al. An antisense inhibitor of apolipoprotein C-III substantially decreases fasting apolipoprotein C-III and triglyceride levels in LPL deficiency. J Clinical Lipidol 2014;8:353-4.
142. Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013; 112:1479-90.
143. Huff MW, Hegele RA. Apolipoprotein C-III: going back to the future for a lipid drug target. Circ Res 2013;112:1405-8.
144. Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide. JAMA Intern Med 2014;174:443-7.
145. Ables GP, Yang KJ, Vogel S, et al. Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. J Lipid Res 2012;53:2364-79.
146. Cheng, D, Iqbal J, Devenny J, et al. Acylation of acylglycerols by acyl coenzyme A:diacylglycerol acyltransferase 1 (DGAT1). Functional importance of DGAT1 in the intestinal fat absorption. J Biol Chem 2008;283:29802-11.
147. Harris CA, Haas JT, Streeper RS, et al. DGAT enzymes are required for triacylglycerol synthesis and lipid droplets in adipocytes. J Lipid Res 2011; 52:657-67.
148. Perry RJ, Samuel VT, Petersen KF, et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014;510:84-91.
149. ClinicalTrials.gov. A Randomized, Doubleblind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. Updated July 3, 2014. Available at: http://clinicaltrials.gov/show/NCT01514461. Accessed September 22, 2014.
150. Meyers CD, Serrano-Wu M, Amer A, et al. The DGAT1 inhibitor pradigastat decreases chylomicron secretion and prevents postprandial triglyceride elevation in humans (abstr). J Clin Lipidol 2013;7:285.
151. Carpentier AC, Frisch F, Labbé SM, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab 2012;97:1635-44.
152. Gaudet D, Méthot J, Déry S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 2013;20:361-9.
153. Ferreira V, Twisk J, Kwikkers K, et al. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther 2014; 25:180-8.
154. Gaudet D, Méthot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol 2012;23:310-20.
155. Kaeppel C, Beattie SG, Fronza R, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med 2013;19:889-91.